PHARMDEKO
PHARMDEKO (PHARMDEKO) is listed on the Nigerian Exchange in the Healthcare sector, with exposure to Pharmaceutical Preparations. This page brings together the current share price, valuation, dividend context, business summary, and a practical 12-week outlook so you can assess the stock faster.
Healthcare
₦397M
N/A
N/A
Current price
₦1.83
Updated Updated 1h ago
12-week outlook signal
P/B
0.39
RSI
41.10
52W high
₦1.83
52W low
₦1.83
Valuation view
Valuation signal is limited
Income view
Income signal not strong yet
Momentum view
Momentum is balanced
Risk view
Lower volatility profile
Business trend
Latest operating data is available
PHARMDEKO is a Nigerian healthcare company that develops, manufactures and supplies pharmaceutical preparations and related health products. It makes money by selling those medicines and products to pharmacies, hospitals, distributors and other customers, earning revenue from product sales and distribution.
Investors usually follow PHARMDEKO for its valuation signal, sector position, and upcoming company events. The goal here is not just to show numbers, but to explain what they mean in plain English.
Latest revenue
₦470M
Most recent reported period.
Debt / equity
0.03
Lower is usually safer.
P/B ratio
0.39
Useful for book value support.
Explain the key numbers
Market cap
₦397M
Market cap is the total value of all shares. Bigger caps are often more stable; smaller caps can move faster but carry higher risk.
No recent dividend record in the current dataset.
Estimated earnings date
2026-02-09
PHARMDEKO
PHARMDEKO
Price: ₦1.83
P/E: N/A
Yield: N/A
AUSTINLAZ
AUSTINLAZ
Price: ₦3.73
P/E: N/A
Yield: N/A
FIDSON
FIDSON
Price: ₦99.50
P/E: 24.16
Yield: 1.51%
MAYBAKER
MAYBAKER
Price: ₦37.90
P/E: 14.74
Yield: 1.02%
Price updated
0d ago
Fundamentals updated
0d ago
Market cap
₦397M
Previous close
₦1.83
52-week range
₦1.83 – ₦1.83
Beta
0.02
RSI
41.10
Latest revenue
₦470M
Book value / share
4.66
Liquidity data is limited right now. Use small position sizes and assume exits can be slow.
Caution: this name may be hard to sell quickly without moving price.
Compare mode →AI Expert analysis →Login to use AI Analyst.
There is no recent dividend record in the current data, which reduces the income case.